Diabetic Neuropathy and MSC Stem Cells

Foot,Pain,,Sore,Feet,Of,Young,Thai,Asian,Woman,And

Diabetic neuropathy is a debilitating and potentially fatal condition caused by damage to the nervous system. The most common form of diabetic neuropathy is peripheral neuropathy, which affects the nerves in the extremities. Symptoms can range from mild tingling and numbness to severe pain and paralysis. There is no cure for diabetic neuropathy, but treatments are available to help relieve the symptoms. One promising treatment option is the use of mesenchymal stem cells (MSCs). MSCs are a type of adult stem cell that can be found in a variety of tissues, including the bone marrow. MSCs have the ability to differentiate into a number of different cell types, including nerve cells. This makes them a potentially valuable treatment option for diabetic neuropathy. In animal studies, MSCs have been shown to improve nerve function and reduce neuropathic pain. In one study, rats with diabetic neuropathy that were treated with MSCs showed significantly improved nerve function and reduced pain compared to those that did not receive treatment. human studies are still in the early stages, but there is some evidence that MSCs may be effective in treating diabetic neuropathy. In one study, patients with diabetic neuropathy who received MSCs showed improvements in nerve function and pain compared to those who did not receive treatment. The use of MSCs is a promising treatment option for diabetic neuropathy, but more research is needed to determine their safety and effectiveness in humans.

 "Mesenchymal stem cells to treat diabetic neuropathy - NCBI." 11 Jul. 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979500/. Accessed 21 Oct. 2022.

 "Bone Marrow-Derived Mesenchymal Stem Cells Improve Diabetic ...." https://pubmed.ncbi.nlm.nih.gov/25975801/. Accessed 21 Oct. 2022.

 "Bone marrow-derived mesenchymal stem/stromal cells reverse the ...." 22 Jun. 2018, https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1224-3. Accessed 21 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
IV50,000,0003150,000,000
Myers cocktail/NAD50,000,0001N/A
Subcutaneous50,000,000150,000,000
Total200,000,000